Mobile

An open-label extension to a 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tole...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-012395-27

An open-label extension to a 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To evaluate the safety and tolerability of repeated injections of 150μg CAD106 in AD patients over the 66 weeks of the Extension study. • To evaluate the antibody response of repeated injections of CAD106 as measured by the titers levels of Aβ-specific IgG in serum in AD patients over the 66 weeks of the Extension study. For a detailed description of the Study objectives, please refer to Section 2 of the enclosed protocol.

Critère d'inclusion

  • Alzheimer's disease

Liens